AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06092268
Drug: SHR-A2009 for injection；Adebrelimab Injection
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy.
Trial: NCT05625555
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Ketamine infusion 0.5mg/kg over 40 minutes
Trial: NCT05625555
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Midazolam infusion 30μg/kg over 40 minutes
Trial: NCT05163249
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Trial: NCT05163249
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Trial: NCT03909594
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine
Trial: NCT03909594
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine
Trial: NCT06415500
Drug: NK042
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NK042 intraperitoneal infusion on Days 0,7 and 14.
Trial: NCT05155189
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tyrosine kinase inhibitors
Trial: NCT05155189
Drug: PD-1(L1) monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors, ICIs
Trial: NCT05569590
Drug: Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
Trial: NCT05569590
Drug: hydrogen peroxide 35%
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrogen peroxide 35%
Trial: NCT05928546
Drug: Quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket .
Trial: NCT00000776
Drug: Flucytosine
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000776
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000776
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000776
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04801056
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TB006 monoclonal antibody
Trial: NCT00037089
Drug: UFT (Tegafur/Uracil)
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05861986
Drug: risdiplam
RxNorm normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Trial: NCT00000705
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06054750
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
Trial: NCT04896697
Drug: vilastobart (XTX101)
RxNorm normalized name: Vilastobart
DrugBank: Vilastobart (DB19327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vilastobart (XTX101) monotherapy
Trial: NCT04896697
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
Trial: NCT04896697
Drug: vilastobart (XTX101)
RxNorm normalized name: Vilastobart
DrugBank: Vilastobart (DB19327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In combination with Atezolizumab
Trial: NCT05492877
Drug: Mitiperstat (AZD4831)
RxNorm normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage, once daily.
Trial: NCT05855967
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT06652165
Drug: zanubrutinib combined with BEAM
RxNorm normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Trial: NCT06652165
Drug: BEAM
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Trial: NCT05069870
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole, capsule, oral
Trial: NCT05069870
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil, capsule, oral
Trial: NCT05069870
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin, capsule, oral
Trial: NCT05199649
Drug: SintilimabCombined With Chemotherapy
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
Trial: NCT06532240
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
Trial: NCT06231771
Drug: Allogeneic mesenchymal stem cells (MSCs)
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
Trial: NCT05667077
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
Trial: NCT06421103
Drug: Indocyanine Green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
Trial: NCT05977738
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Pitavastatin administration
Trial: NCT06153004
Drug: Antidepressant medication (ADM)
RxNorm normalized name: THP-Adm
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
Trial: NCT05317780
Drug: rAAV9-CB6-AspA
RxNorm normalized name: rAAV9-rsATP7A
DrugBank: rAAV9-rsATP7A (DB17664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
Trial: NCT00040560
Drug: 111In-DAC
RxNorm normalized name: DAC
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05867329
Drug: Cyclosporine Injection (IV)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers.
Trial: NCT05867329
Drug: Cyclosporine Oral Product
RxNorm normalized name: cyclosporine Oral Product
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician.
Trial: NCT05867329
Drug: Upadacitinib Extended Release Oral Tablet
RxNorm normalized name: upadacitinib Extended Release Oral Tablet
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital.
Trial: NCT05867329
Drug: Prednisone Oral Product
RxNorm normalized name: prednisone Oral Product
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Trial: NCT06084780
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
Trial: NCT06084780
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
Trial: NCT06084780
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
Trial: NCT06261814
Drug: Sulfur Hexafluoride Lipid Microspheres
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05171062
Drug: bexmarilimab (FP-1305)
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Bexmarilimab (DB16383)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
Trial: NCT05171062
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
Trial: NCT04497038
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
Trial: NCT00000722
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05520892
Drug: intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
Trial: NCT04941170
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
Trial: NCT04941170
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
Trial: NCT05544136
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
Trial: NCT05563155
Drug: Dexamethasone 24 mg
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 24 mg on day 1 after surgery.
Trial: NCT04662086
Drug: Acebilustat
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule administered orally once daily
Trial: NCT04662086
Drug: Camostat
RxNorm normalized name: camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
Trial: NCT06259760
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
Trial: NCT05648669
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg tablet
Trial: NCT05648669
Drug: Elagolix placebo
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix-matched Placebo tablet
Trial: NCT05191914
Drug: Chidamide+ Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
Trial: NCT06652139
Drug: selinexor combined with BEAM regimen
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
Trial: NCT05675644
Drug: Drospirenone-only pill
RxNorm normalized name: drospirenone Pill
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose based on adaptive dose-finding design
Trial: NCT05533229
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The trial aims to study the quality of anesthesia, perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
Trial: NCT05901389
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Trial: NCT00995059
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00995059
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00995059
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00995059
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT00995059
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given oral or IV
Trial: NCT06516926
Drug: SHR-4602
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, cycle every 21 days;
Trial: NCT05316935
Drug: GnRHa
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
Trial: NCT05316935
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg po qd and no more than 24 weeks